In summary, our results of study supported the concept that LDL-C is a key role in the pathogenesis of ASCVD and the capacity of medication to lower of LDL-C regardless of statin or non-statin therapies (ezetimibe and PCSK9 inhibitors) is definitely the first concern rather than the pleiotropic effects. The gene discussed is PCSK9; the disease is atherosclerosis.